Even though there is no statistically significant difference among subtypes in lymph node metastases, our findings of increased nodal involvement in HER-2+ subtypes may at least partly explain the observed increase in local recurrence in the HER-2+ subtype in this study. Here, ERBB2 is linked to metastatic malignant neoplasm in the lymph nodes.